Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LPCN | US
-0.24
-4.79%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
19/09/2024
4.77
5.13
5.29
4.74
Lipocine Inc. a clinical-stage biopharmaceutical company engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148 a novel prodrug of testosterone testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144 an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis which has completed Phase II testing; LPCN 1111 an oral TRT product of testosterone tridecanoate for once daily dosing which has completed Phase II clinical testing; and LPCN 1107 an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City Utah.
View LessPositive Momentum
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
75.3%1 month
62.9%3 months
89.1%6 months
102.1%-
-
1.16
-
-
0.65
0.44
-
-9.67M
25.51M
25.51M
-
-3.68K
-
13.75K
-34.12
4.81
2.59
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.09
Range1M
2.12
Range3M
6.39
Rel. volume
1.49
Price X volume
263.64K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3487 | 26.37M | 2.56% | n/a | 4.33% |
MEI Pharma Inc | MEIP | Drug Manufacturers-Specialty & Generic | 3.14 | 20.92M | 3.29% | 0.77 | 22.86% |
Flora Growth Corp. Common Stock | FLGC | Drug Manufacturers-Specialty & Generic | 1.42 | 18.98M | 35.24% | n/a | 76.81% |
Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 1.28 | 18.04M | 2.40% | n/a | 81.86% |
Guardion Health Sciences Inc | GHSI | Drug Manufacturers-Specialty & Generic | 10.85 | 13.93M | 3.63% | n/a | 0.00% |
BGXX | BGXX | Drug Manufacturers-Specialty & Generic | 0.06 | 11.47M | -59.49% | n/a | 5.20% |
Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 0.3412 | 8.07M | -4.16% | n/a | 13.87% |
Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 1.28 | 7.10M | -0.78% | n/a | 13.20% |
Imc Mortgage Co | IMCC | Drug Manufacturers-Specialty & Generic | 2.15 | 4.80M | -4.02% | n/a | 222.75% |
Sonoma Pharmaceuticals Inc | SNOA | Drug Manufacturers-Specialty & Generic | 3.83 | 3.93M | -10.93% | n/a | 8.44% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.751 | 1.10M | 24.54% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 915.21K | -8.33% | n/a | -37.05% |
Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 14.31 | 0 | 0.35% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.65 | 16.67 | Cheaper |
Ent. to Revenue | 0.44 | 309.37 | Cheaper |
PE Ratio | - | 29.14 | - |
Price to Book | 1.16 | 12.81 | Cheaper |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 89.11 | 75.12 | Par |
Debt to Equity | - | -0.93 | - |
Debt to Assets | - | 0.45 | - |
Market Cap | 25.51M | 5.22B | Emerging |